1. Introduction

Artificial placenta technology is an emerging area of biotechnology that seeks to support extremely premature fetuses in a fluid-filled, womb-like environment outside the pregnant person's body. Related technologies, sometimes called artificial womb systems or extrauterine fetal support systems, aim to provide conditions that resemble aspects of the natural uterine environment, potentially allowing fetal development to continue after delivery at a very early gestational age.

The technology raises important legal questions concerning medical negligence, product liability, informed consent, experimental treatment, parental decision-making, fetal interests, and institutional accountability.

Artificial placenta liability standards refers to the legal principles used to determine whether a manufacturer, clinician, hospital, researcher, or other responsible party should be held liable for injury, death, developmental impairment, or other harm arising from the design, manufacture, testing, or use of an artificial placenta system.

An important qualification is that, as of October 2026, there is no single, universally established body of law specifically governing artificial placenta liability. The analysis must therefore draw on existing medical negligence, product liability, biomedical research, reproductive rights, and constitutional principles. The cases discussed below are relevant legal precedents by analogy; they should not be mistaken for judgments that directly determine liability for artificial placenta technology.

2. Nature of artificial placenta liability

Liability can arise at several stages of the technology's lifecycle.

Research and clinical trials

Potential liability for inadequate risk assessment, unethical experimentation, defective protocols, insufficient consent, or failure to monitor participants.

Design and manufacture

Potential liability for unsafe fluid circulation, oxygenation failure, infection risks, sensor defects, alarms, software, or inadequate manufacturing controls.

Clinical use

Potential liability for improper patient selection, technical errors, delayed intervention, inadequate supervision, or failure to respond to complications.

Long-term follow-up and governance

Potential responsibility for inadequate follow-up arrangements, misleading safety claims, deficient adverse-event reporting, or breaches of applicable research and privacy duties.

The central legal question is whether a recognised duty was breached and whether that breach caused legally compensable harm. The mere occurrence of a poor outcome does not automatically establish liability.

3. Essential elements of liability

A claimant will generally need to establish the following elements, subject to the applicable jurisdiction and cause of action.

Duty of care: The defendant owed a legal duty to the child, pregnant patient, research participant, or another person entitled to protection.

Breach of duty: The defendant failed to meet the applicable standard of professional care, product safety, research ethics, or statutory compliance.

Causation: The breach caused or materially contributed to the alleged injury, according to the applicable legal test.

Actual harm: The claimant suffered a legally recognised injury, such as physical damage, additional medical expenses, loss of a legally recognised interest, or another compensable loss.

Remedy and attribution: The court must determine which defendant is legally responsible and what compensation or other remedy is available.

The Supreme Court of India explained the foundational relationship between duty, breach, and resulting damage in Jacob Mathew v. State of Punjab (2005). These principles provide a starting point for analysing injuries associated with emerging medical technologies.

Indian Kanoon

+1

4. Major liability categories

A. Medical negligence liability

A clinician may be liable if the clinician fails to exercise the degree of skill and care reasonably expected of a competent practitioner undertaking the relevant procedure.

Potential examples include:

Selecting a patient for artificial-placenta treatment without adequate clinical justification.

Failing to assess whether conventional neonatal intensive care would be safer.

Incorrectly connecting the fetal circulation to the extracorporeal support system.

Failing to monitor oxygenation, blood flow, temperature, fluid balance, or infection.

Ignoring alarms or delaying emergency intervention.

Continuing treatment despite evidence that the system is causing serious harm.

The legal standard must reflect the circumstances, the clinician's role, accepted professional practice, and the evidence available at the relevant time. Because this is an emerging technology, the absence of an established treatment protocol does not automatically prove negligence; equally, experimental status does not excuse careless practice.

B. Product liability

Manufacturers and other supply-chain participants may face claims where a defective device causes injury. Depending on the governing law, relevant theories include negligence, defective design, manufacturing defects, inadequate warnings, breach of warranty, and statutory product liability.

A manufacturer is not automatically liable for every adverse outcome. The claimant must satisfy the relevant statutory or common-law requirements, including causation where required.

C. Research and clinical-trial liability

Artificial placenta research presents distinct risks because the technology may be insufficiently validated for human use. Liability may arise where researchers or institutions fail to obtain required approvals, use an unjustified experimental protocol, inadequately disclose material risks, disregard stopping criteria, or fail to report adverse events.

The relevant responsibilities may be distributed among:

The principal investigator and treating clinical team.

The research institution and ethics committee.

The device manufacturer and trial sponsor.

The hospital responsible for monitoring and emergency care.

Other entities with legally recognised duties under the applicable research framework.

A signed consent form is not a complete defence to negligent treatment, an unlawful research procedure, or a defective device. The legal validity of consent depends on the information provided, the participant's decision-making capacity, voluntariness, and applicable law.

D. Hospital and institutional liability

A hospital may face direct liability for deficient staffing, inadequate equipment maintenance, poor infection control, insufficient training, or unsafe clinical protocols. It may also face vicarious liability for the acts of employees or other personnel where the relevant legal relationship and rules of attribution permit it.

In artificial-placenta treatment, an institution should have a clear allocation of responsibility for continuous monitoring, emergency transfer, system failure, clinical decision-making, and escalation of care. Unclear responsibilities can create both patient-safety risks and evidentiary difficulties when an injury occurs.

5. Leading case laws and their application

The following decisions establish principles that can be applied by analogy to artificial placenta disputes.

Case 1: Jacob Mathew v. State of Punjab (2005)

Supreme Court of India · (2005) 6 SCC 1

Facts and issue: The case concerned allegations of medical negligence following a patient's death and the standards required to establish criminal negligence by a medical professional.

Legal principle: The Supreme Court distinguished ordinary negligence from the degree of gross negligence or recklessness required for criminal medical liability. It emphasised the importance of duty, breach, and resulting damage in negligence analysis. Criminal liability requires more than an adverse outcome or a mere error of judgment.

Application to artificial placenta technology: Suppose a neonatologist uses an artificial placenta system and the infant suffers brain injury after a sudden oxygenation failure. The injury alone does not establish criminal negligence. The court would examine whether the clinician's conduct fell below the applicable standard and, for criminal liability, whether the required heightened degree of negligence was established.

Significance: This case is especially important in India because it helps distinguish a civil compensation claim from a criminal prosecution.

Indian Kanoon

+2

Case 2: V. Kishan Rao v. Nikhil Super Speciality Hospital (2010)

Supreme Court of India · (2010) 5 SCC 513

Facts and issue: The case concerned a consumer complaint alleging deficient medical treatment and the circumstances in which expert medical evidence is necessary.

Legal principle: The Supreme Court rejected an inflexible rule that expert evidence must be obtained in every medical negligence complaint. Whether expert evidence is required depends on the nature and complexity of the issue.

Application to artificial placenta technology: Claims involving fetal blood circulation, oxygen transfer, specialised monitoring, or developmental outcomes will commonly require expert evidence. However, a plainly documented failure to follow an essential safety procedure may sometimes be evaluated without requiring a separate expert opinion on every issue.

Significance: The decision supports a fact-sensitive approach to proof. Expert evidence should assist the court in understanding the technology and the applicable standard of care rather than operate as an automatic procedural barrier to a legitimate claim.

CDN BBSR

+1

Case 3: Montgomery v. Lanarkshire Health Board (2015)

UK Supreme Court · [2015] UKSC 11

Facts and issue: The case concerned a doctor's failure to inform a pregnant patient of a material risk associated with childbirth and the availability of an alternative delivery method.

Legal principle: The Court held that doctors must take reasonable care to ensure patients are aware of material risks and reasonable alternative treatments. A risk is material if a reasonable person in the patient's position would likely attach significance to it, or the doctor should reasonably know that the particular patient would do so.

Application to artificial placenta technology: Before an elective or experimental intervention, clinicians should explain material risks, the uncertainties surrounding long-term development, the realistic alternatives, and the potential consequences of declining the proposed treatment. Where appropriate, the discussion should include the distinction between established neonatal intensive care and investigational artificial-placenta support.

Significance: This is a leading authority on informed consent in the UK. Its precise legal effect depends on jurisdiction, but its emphasis on patient autonomy provides a useful comparative framework.

UK Supreme Court

+1

Case 4: Donoghue v. Stevenson (1932)

House of Lords · [1932] AC 562

Facts and issue: A consumer alleged illness after drinking ginger beer from a bottle containing a decomposed snail. The case addressed the manufacturer's duty of care to the ultimate consumer.

Legal principle: The decision became a foundational authority for the modern law of negligence and the duty owed by manufacturers to people foreseeably harmed by their products.

Application to artificial placenta technology: A manufacturer may owe duties to foreseeable users and patients affected by the device, even where the injured person did not purchase it directly. A defect in a sealed oxygenation component, for example, may expose an infant to foreseeable injury.

Significance: The case provides a foundation for analysing manufacturer negligence. It does not, by itself, establish that every defective medical device attracts automatic or strict liability; the applicable jurisdiction's product-liability rules remain important.

Donoghue v. Stevenson Case Report

+1

Case 5: Bolam v. Friern Hospital Management Committee (1957)

English Queen's Bench · [1957] 1 WLR 582

Facts and issue: The case concerned whether medical treatment met the standard of a reasonably competent practitioner.

Legal principle: The traditional Bolam approach asks whether the practitioner acted in accordance with a responsible body of professional medical opinion. Its application and limits vary by jurisdiction and type of duty; it is not a universal defence to negligence.

Application to artificial placenta technology: Expert evidence may be used to determine whether a clinician's patient-selection, monitoring, or emergency-management decisions were professionally reasonable in the circumstances. But a court must also consider applicable statutory duties and jurisdiction-specific rules on disclosure, safety, and consent.

Significance: The case illustrates why courts require specialised evidence when assessing complex medical decisions. In the UK, Montgomery established a distinct patient-centred approach to disclosure of material risks rather than simply applying Bolam to that question.

CDN BBSR

+1

Case 6: State of Punjab v. Shiv Ram (2005)

Supreme Court of India · (2005) 7 SCC 1

Legal relevance: This decision is commonly discussed in Indian medical negligence law concerning allegations arising from sterilisation procedures and the distinction between an unsuccessful medical outcome and negligent performance.

Application to artificial placenta technology: A child experiencing a complication or an unfavourable developmental outcome does not, without more, prove that the device or clinical procedure was negligent. The claimant must establish the applicable elements of liability, while the defendant's compliance with proper standards must be evaluated on the evidence.

Significance: The broader lesson is that a medical intervention does not ordinarily guarantee a particular result. However, the principle does not excuse defective equipment, inadequate disclosure, or negligent care.

These precedents should be read alongside the specific statutory framework and the factual evidence in any actual artificial-placenta claim.

6. Indian statutory framework

For a dispute arising in India, several legal frameworks may be relevant.

A. Consumer Protection Act, 2019

The Act's product-liability provisions are particularly important for defective medical devices and deficient healthcare services where the statutory requirements are satisfied.

Section 82: Establishes the application of the product-liability chapter to claims involving harm caused by a defective product.

Section 83: Provides for product-liability actions against manufacturers, product service providers, or product sellers, as applicable.

Section 84: Addresses manufacturer liability, including manufacturing defects, defective design, deviation from specifications, express warranties, and inadequate instructions or warnings.

Section 86: Specifies circumstances in which a product seller other than the manufacturer may be liable.

Section 87: Sets out exceptions to product-liability actions.

These provisions may be relevant where an artificial placenta device causes injury because of a manufacturing defect, unsafe design, inadequate warnings, or a qualifying deficiency in service. Their application depends on the statutory definitions, exclusions, and facts of the case.

IndiaCode

+4

B. Medical negligence and professional duties

Indian civil law, consumer law, and applicable professional regulations may impose different duties on clinicians and institutions. A claimant may need to establish deficient treatment, breach of an applicable professional duty, causation, and compensable harm.

Criminal liability is a separate question. The applicable criminal statute and its requirements must be examined in light of the date of the conduct and the nature of the alleged negligence. A civil negligence finding does not automatically establish a criminal offence.

C. Biomedical research and device regulation

Where artificial placenta treatment is investigational, the applicable medical-device requirements, research ethics rules, institutional approvals, and clinical-trial conditions must be identified. Approval to conduct research does not necessarily establish that every subsequent treatment decision was reasonable, nor does it eliminate liability for a negligent act.

The exact regulatory pathway would depend on the device's intended use, technical characteristics, clinical setting, and the rules in force at the relevant time.

7. Causation and scientific evidence

Causation is likely to be one of the most difficult issues in artificial placenta litigation.

An infant born extremely prematurely may experience complications because of prematurity, pre-existing conditions, the intervention required for transfer, the artificial placenta system, or several interacting factors. The claimant must establish the causal connection required by the relevant law.

Courts may examine:

Clinical records documenting fetal and neonatal condition before and after transfer.

Oxygenation and blood-flow data recorded by the device.

Alarm logs, software records, maintenance history, and technical failure reports.

Expert evidence from neonatologists, biomedical engineers, and other relevant specialists.

Evidence distinguishing the natural risks of extreme prematurity from additional harm attributable to the intervention.

Research on artificial amnion and placenta technology has identified unresolved legal questions, including how the law should characterise the death of a developing entity sustained by such a system. This demonstrates that existing legal concepts may not resolve every factual and legal problem created by the technology.

PubMed Central (PMC)

+1

Hypothetical illustration

Suppose an artificial placenta device develops a circulation fault, causing a premature infant to suffer neurological injury.

If a manufacturing defect caused the fault, the manufacturer may face product-liability claims.

If the hospital failed to maintain the device as required, institutional or service-provider liability may arise.

If the clinician ignored a clear alarm and failed to intervene, clinical negligence may be established.

If multiple failures contributed to the injury, more than one defendant may be responsible, depending on the applicable rules of causation and allocation of liability.

This is illustrative only. The outcome would depend on the evidence and governing law.

8. Defences and limitations

Potential defendants may raise several arguments, subject to the applicable legal framework.

Importantly, the experimental nature of a treatment is not a blanket defence. Researchers, manufacturers, hospitals, and clinicians remain subject to the duties imposed by the applicable law.

9. Recommended artificial placenta liability standards

A sound regulatory framework should establish clear responsibilities before human use becomes routine.

Preclinical validation and independent review

Require evidence of safety, reproducible performance, and independent assessment before progression to human trials.

Enhanced informed consent

Explain uncertainties, foreseeable risks, alternatives, and the limits of available long-term outcome data.

Continuous monitoring and traceability

Preserve physiological measurements, device logs, clinical decisions, maintenance records, and adverse-event reports.

Clear allocation of responsibility

Identify the duties of manufacturers, hospitals, clinicians, sponsors, and research institutions, including responsibility for emergency intervention.

Long-term follow-up and compensation

Establish proportionate developmental follow-up, transparent reporting, and appropriate routes to compensation where legally actionable harm occurs.

These are proposed safeguards rather than a statement that every jurisdiction already imposes each requirement specifically for artificial placenta systems.

10. Conclusion

Artificial placenta liability requires a careful combination of medical negligence principles, product-safety rules, informed-consent obligations, research ethics, and causation analysis.

The most important precedents are Jacob Mathew v. State of Punjab for the distinction between ordinary and criminal medical negligence, V. Kishan Rao v. Nikhil Super Speciality Hospital for the evidentiary approach to medical negligence, Montgomery v. Lanarkshire Health Board for material-risk disclosure, and Donoghue v. Stevenson for the manufacturer's duty of care.

In India, the Consumer Protection Act, 2019 may provide a significant statutory route where its product-liability requirements are satisfied. Nevertheless, there is not yet a settled, technology-specific judicial standard for artificial placenta liability. Any claim must therefore be assessed through existing legal principles, the applicable regulatory requirements, expert scientific evidence, and the particular facts.

For academic research, the central issue is how the law can protect the developing child and other affected persons without treating every adverse experimental outcome as proof of negligence or allowing technological novelty to excuse preventable harm.